OptiBiotix Health - Director’s Dealing
Released
Released
Announcement PDF
RNS Number : 6614V
OptiBiotix Health PLC
16 April 2021
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director's Dealing
OptiBiotix
Health
plc
(AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that it received notification on
15 April 2021 that Mr Stephen Hammond, a recently appointed NonExecutive Director of the Company (RNS 2 nd February 2021), acquired
25,000 ordinary shares in the Company on 15 April 2021, representing
0.03% of the Company's issued share capital, at an average price of 51.8
pence per share.
Mr Hammond did not hold any ordinary shares in the Company prior to the
above transaction.
This announcement contains inside information for the purposes of the UK
Market Abuse Regulation and the Directors of the Company are responsible
for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: 020 7213 0880
Cenkos Securities plc (Broker)
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Tel: 020 7397 8900
Walbrook PR Ltd
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human
microbiome - the collective genome of the microbes in the body - in order to
prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which
are used as active ingredients and supplements. More than twenty
international food and healthcare supplement companies have signed
agreements with OptiBiotix to incorporate their human microbiome
modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and
health products. The Company's current areas of focus include obesity,
cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
2
Reason for
notification
a.
Position/Status
Non-Executive Director
b.
Initial notification/
Initial Notification
Stephen Hammond
Amendment
3
Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a.
Name
OptiBiotix Health Plc
b.
LEI
213800UKYQFT941QHS14
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a.
Description of the
financial instrument,
type of instrument
Identification Code
b.
Nature of the
transaction
25,000 ordinary shares of 2p each
ISIN: GB00BP0RTP38
Purchase of 25,000 ordinary shares in the Company
c.
d.
Price(s) and volume(s)
Price(s) per share
Volume(s)
51.8p
25,000
Aggregated information
-
Volume
-
Price
n/a
e.
Date of the transaction
15 April 2021
f.
Place of the transaction
London Stock Exchange, AIM
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the
Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions
relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with
the information contained in this communication, and to share such analysis on an anonymised basis with others as
part of our commercial services. For further information about how RNS and the London Stock Exchange use the
personal data you provide us, please see our Privacy Policy.
END
DSHBCGDSIXBDGBU
Share your feedback
Discover